For example, peripheral blood lymphocytes with modified mTCR targeting KRAS G12D (NCT03745326, Phase I/II) and KRAS G12V (NCT03190941, Phase I/II) mutations are under clinic evaluation for rectal and pancreatic cancer, respectively [41,44]. Here, KRAS is linked to familial pancreatic carcinoma.